Saxenda 3mg Liraglutide Subcutaneous Injection Pen

Saxenda 3mg Liraglutide Subcutaneous Injection Pen contains liraglutide, a glucagon-like peptide-1 receptor agonist, commonly known as a GLP-1 receptor agonist. It is a prescription-only subcutaneous injection medicine intended for use under the supervision of a licensed healthcare professional.

Saxenda is typically administered once daily by subcutaneous injection, as prescribed. It is commonly used as part of a doctor-supervised weight-management plan that may include reduced-calorie diet, increased physical activity, behavioural support, and regular medical monitoring.

This product listing refers to a liraglutide subcutaneous injection pen. Use only as directed by a healthcare professional.

Product Information

• Product Name: Saxenda 3mg Liraglutide Subcutaneous Injection Pen
• Japanese Name: サクセンダ皮下注 3mg リラグルチド注射ペン
• Chinese Name: Saxenda 3mg 利拉魯肽皮下注射筆
• Active Ingredient: Liraglutide
• Strength: 3mg
• Dosage Form: Subcutaneous injection pen
• Route of Administration: Subcutaneous
• Drug Class: GLP-1 receptor agonist
• Brand Owner: Novo Nordisk
• Product Type: Prescription medicine
• Use: Use only as directed by a licensed healthcare professional

What Is Saxenda 3mg Liraglutide Subcutaneous Injection Pen?

Saxenda 3mg Liraglutide Subcutaneous Injection Pen is a prefilled injection pen containing liraglutide for subcutaneous administration. Liraglutide belongs to the GLP-1 receptor agonist class of medicines. GLP-1 receptor agonists act on receptors involved in appetite regulation, satiety signaling, gastric emptying, and metabolic control.

Saxenda is generally prescribed as part of a comprehensive medical weight-management plan. Treatment decisions should be based on a healthcare professional’s assessment of body weight, BMI criteria, weight-related health conditions, medical history, current medicines, and overall suitability.

This medicine should not be used without a prescription or professional medical supervision.

Key Features

Saxenda 3mg Liraglutide Subcutaneous Injection Pen is known for:

• Contains liraglutide
• 3mg strength
• Subcutaneous injection pen
• Typically administered once daily as prescribed
• GLP-1 receptor agonist medicine
• Used as part of a doctor-supervised weight-management plan
• Manufactured by Novo Nordisk
• Prescription-only medicine
• Intended for healthcare professional-directed use

About Liraglutide

Liraglutide is a GLP-1 receptor agonist. It acts on GLP-1 receptors involved in appetite regulation and metabolic pathways.

Under healthcare professional guidance, liraglutide may help support:

• Appetite regulation
• Satiety and fullness signaling
• Reduced food intake as part of a treatment plan
• Slower gastric emptying
• Weight-management care
• Metabolic health monitoring

Individual suitability, response, and tolerability vary. Your healthcare provider will decide whether Saxenda is appropriate based on your medical history and treatment goals.

Dose Strength Information

The 3mg dose is commonly considered the target maintenance dose for Saxenda treatment after gradual dose escalation, if tolerated and clinically appropriate. Patients are usually started at a lower dose and increased gradually according to the prescribed treatment schedule.

A doctor may review:

• Treatment suitability
• Dose-escalation schedule
• Digestive tolerability
• Treatment response
• Current medications
• Weight-management goals
• Blood glucose status
• Medical history and contraindications

Patients should not increase, decrease, skip, restart, or stop doses without medical advice.

How to Use Saxenda 3mg Liraglutide Subcutaneous Injection Pen

Use exactly as directed by your doctor, pharmacist, or healthcare provider.

General administration guidance may include:

• Inject under the skin as prescribed.
• Common injection areas may include abdomen, thigh, or upper arm.
• Saxenda is typically used once daily when prescribed.
• Use at around the same time each day if instructed.
• Do not inject into a vein or muscle.
• Rotate injection sites.
• Do not share injection pens with others.
• Use a new needle for each injection if applicable.
• Follow the official instructions for use supplied with the medicine.

Always read the patient information leaflet and follow healthcare professional guidance.

Who May Be Prescribed Saxenda 3mg Liraglutide Subcutaneous Injection Pen?

Saxenda may be prescribed to suitable adult patients as part of a healthcare professional-supervised treatment plan.

A healthcare professional may assess:

• Body weight and BMI criteria
• Weight-related health conditions
• Medical history
• Current medications
• Previous GLP-1 medicine use
• Digestive system conditions
• Pancreatitis risk
• Gallbladder disease risk
• Kidney function
• Diabetes status
• Pregnancy or breastfeeding status
• Ability to safely use an injectable medicine

This product is not suitable for everyone and should only be used after medical assessment.

Important Safety Information

Before using Saxenda 3mg Liraglutide Subcutaneous Injection Pen, tell your healthcare provider if you:

• Have a history of pancreatitis
• Have gallbladder problems
• Have severe stomach or intestinal disease
• Have kidney disease
• Have liver disease
• Have diabetes or use diabetes medication
• Have diabetic retinopathy
• Have a history of thyroid tumors or endocrine disorders
• Are pregnant, planning pregnancy, or breastfeeding
• Have allergies to liraglutide or any ingredient in the injection
• Are taking any prescription, over-the-counter, or herbal medicines

Possible Side Effects

Common side effects may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain or discomfort
• Indigestion
• Bloating
• Headache
• Fatigue
• Dizziness
• Injection site reaction

Serious side effects may occur and require medical attention.

Seek medical help immediately if you experience:

• Severe or persistent abdominal pain
• Severe vomiting or dehydration
• Signs of pancreatitis
• Signs of gallbladder problems
• Allergic reaction
• Severe hypoglycemia symptoms, especially if used with diabetes medicine
• Vision changes
• Neck lump, difficulty swallowing, or persistent hoarseness
• Persistent mood changes or suicidal thoughts

Storage

Store according to the product package and pharmacist instructions.

General storage recommendations:

• Keep in original packaging.
• Store refrigerated if required by product instructions.
• Do not freeze.
• Protect from heat and direct sunlight.
• Keep out of reach of children and pets.
• Do not use after the expiry date.
• Dispose of used needles and pens safely according to local guidance.

Important Notes

• Saxenda 3mg Liraglutide Subcutaneous Injection Pen is a prescription medicine.
• Use only under healthcare professional supervision.
• Do not share injection pens.
• Do not use for casual or cosmetic weight loss without medical indication.
• Dose adjustment should only be made by a healthcare professional.
• It should be used as part of a comprehensive medical weight-management plan.
• Individual response and tolerability may vary.
• Saxenda should not be used together with another GLP-1 receptor agonist unless specifically directed by a healthcare professional.

Disclaimer

This product page is for general product information only and does not replace professional medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.

Saxenda is a prescription medicine. Use only under the supervision of a licensed healthcare professional. This product information is for reference only and does not replace medical advice, diagnosis, or treatment.